Dr. Goy on Combinations With Novel Agents in Relapsed/Refractory MCL

Video

In Partnership With:

Andre Goy, MD, MS, discusses the utility of combinations with novel agents in the treatment of patients with relapsed/refractory mantle cell lymphoma.

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the utility of combinations with novel agents in the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL).

The addition of ibrutinib (Imbruvica) to rituximab (Rituxan) and lenalidomide (Revlimid), or venetoclax (Venclexta) alone has demonstrated high complete response rates in patients with relapsed/refractory MCL, says Goy.

Moving these therapies into the frontline setting may be beneficial for patients who are eligible for intensive therapy, says Goy. For example, the addition of a BTK inhibitor such as ibrutinib or acalabrutinib (Calquence) to the combination of bendamustine and rituximab may provide more durable responses in the frontline setting.

Additionally, chemotherapy-free regimens may be particularly important for elderly patients who are not eligible for chemotherapy, explains Goy. Patients who are not eligible for intensive therapy may not derive a significant benefit from standard cytotoxic induction therapy. As such, ongoing clinical trials are investigating doublet and triplet regimens in the frontline setting, concludes Goy.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute